Just got back from the ePharma Summit in Philadelphia and it’s going to take a couple days to digest, catch up, write up, etc. But here are a few news items for your Thursday:
Two more pharma companies jump aboard YouTube with their own channels – this is a promising direction for companies getting their toes in the water with social media applications.
Promising Phase III data on Zometa’s efficacy in breast cancer reduction – A newly published study in The New England Journal of Medicine shows that in premenopausal women with early breast cancer administering Zometa® (zoledronic acid) along with post-surgery hormone therapy provided a reduction in risk of recurrence or death that was 36% beyond that achieved with hormone therapy alone.
Atacand and kidney failure prevention? Very interesting. And, will Sanofi’s Multaq make it to market this time?
Rumor mill – Sanofi and Biogen?
For the Record – a quick muse on how I really feel about the pharma industry…
——
Subscribe to the Impactiviti blog via e-mail
Subscribe to the Impactiviti blog via RSS
Connect with Steve Woodruff
.
![Reblog this post [with Zemanta]](https://i0.wp.com/img.zemanta.com/reblog_e.png)
Impactiviti blog 